WebDisclosure WebDisclosure
Basculer en Français
9560 Companies
188851 Keywords
120589 Articles
100789 Press releases
Headlines Articles Press releases Harvard Eye Associates Remove
  1. Home
  2. Companies
  3. Harvard Eye Associates
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 02/20/2024 at 17:00, 1 year 10 months ago

    Nouveau traitement révolutionnaire contre le glaucome : l'iDose® TR s'installe chez Harvard Eye Associates

    FDA IDose® TR Glaucoma Harvard Eye Associates Thérapie Oculaire
  • BRIEF

    published on 02/20/2024 at 17:00, 1 year 10 months ago

    New Revolutionary Treatment for Glaucoma: iDose® TR is Now Available at Harvard Eye Associates

    FDA IDose® TR Glaucoma Harvard Eye Associates Eye Therapy
  • PRESS RELEASE

    published on 02/20/2024 at 17:00, 1 year 10 months ago

    Harvard Eye Associates Now Offering iDose(R) TR as a New Treatment Option to Reduce Eye Pressure in Patients With Ocular Hypertension and Open-Angle Glaucoma

    Harvard Eye Associates introduces iDose® TR, a new FDA-approved treatment for glaucoma and ocular hypertension that provides long-duration drug therapy inside the eye. Dr. Teymoorian leads inaugural treatments at Alicia Surgery Center
    IDose® TR Glaucoma Harvard Eye Associates Ocular Hypertension Travoprost Implant
    Logo of Harvard Eye Associates
Accesswire
  • Published on 12/20/2025 at 00:30, 1 day 21 hours ago

    Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025

  • Published on 12/19/2025 at 22:00, 1 day 23 hours ago

    GMV Minerals Inc. Closes Non-Brokered Equity Financing

  • Published on 12/19/2025 at 18:30, 2 days 3 hours ago

    Eagle Plains Shareholders Approve all Matters at Annual General Meeting

  • Published on 12/19/2025 at 14:40, 2 days 7 hours ago

    Northern Superior Announces Closing of the Arrangement

  • Published on 12/19/2025 at 13:30, 2 days 8 hours ago

    Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF

View all ACCESSWIRE
EQS Group
  • Published on 12/21/2025 at 08:55, 12 hours 49 minutes ago

    Vantage Markets recognised for real-time threat intelligence collaboration with Trend Micro

  • Published on 12/20/2025 at 16:45, 1 day 4 hours ago

    Shanghai Electric Powers Up Iraq's Energy Future with Major 625MW Efficiency Upgrade

  • Published on 12/20/2025 at 10:05, 1 day 11 hours ago

    FITUR 2026 highlights the strong synergies between Germany and Spain

  • Published on 12/19/2025 at 22:03, 1 day 23 hours ago

    EAMD: Trading resumes on the Düsseldorf Stock Exchange, lawsuit filed by minority shareholders dismissed, capital increase for investments in drone projects in the defense tech sector

  • Published on 12/19/2025 at 21:40, 2 days ago

    IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries

View all EQS
Les Echos
  • Published on 12/19/2025 at 21:57, 1 day 23 hours ago

    Mise à disposition du document d’enregistrement universel

  • Published on 12/19/2025 at 08:30, 2 days 13 hours ago

    Share capital decrease by way of treasury shares cancellation

  • Published on 12/19/2025 at 08:30, 2 days 13 hours ago

    Réduction du capital par voie d’annulation d’actions propres

  • Published on 12/19/2025 at 07:00, 2 days 14 hours ago

    EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS

  • Published on 12/19/2025 at 07:00, 2 days 14 hours ago

    EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2025 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy